Gilead Sciences Inc Revenue Growth Rates (GILD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gilead Sciences Inc   (NASDAQ: GILD)
 

GILD's Revenue Growth by Quarter and Year

Gilead Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GILD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 7,803.00
1st Quarter March 6,960.00
FY 14,763.00

GILDs Annual Revenue
Gilead Sciences Inc 's Revenue in the fiscal year 2025 $ 29,443.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2024 $ 28,754.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2023 $ 27,116.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2022 $ 27,281.00 millions
Gilead Sciences Inc 's Revenue in the fiscal year 2021 $ 27,305.00 millions




GILD Revenue second quarter 2026 Y/Y Growth Comment
Gilead Sciences Inc reported Revenue increase of 10.18% year on year in the second quarter 2026, to $ 7,803.00 millions, this is lower than Gilead Sciences Inc 's recent average Revenue increase of 18.29%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue growth. While Gilead Sciences Inc ' s Revenue growth of 10.18% ranks overall at the positon no. 2582 in the second quarter 2026.


GILD Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 4.7 % 6.4 % -3.72 %
3rd Quarter September - 2.97 % 7.01 % 0.13 %
2nd Quarter June 10.18 % 1.84 % 5.38 % 5.42 %
1st Quarter March 4.39 % -0.28 % 5.26 % -3.61 %
FY   - 2.4 % 6.04 % -

Financial Statements
Gilead Sciences Inc 's second quarter 2026 Revenue $ 7,803.00 millions GILD's Income Statement
Gilead Sciences Inc 's second quarter 2025 Revenue $ 7,082.00 millions Quarterly GILD's Income Statement


GILD Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2.01 % 0.32 % 0.89 %
3rd Quarter September - 9.7 % 8.5 % 6.85 %
2nd Quarter June 12.11 % 6.22 % 4.01 % 3.89 %
1st Quarter March -12.18 % -11.92 % -6.02 % -14.03 %
FY (Year on Year)   - 2.4 % 6.04 % -


Back to GILD Growth rate Comparisons >> Back to GILD Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #373
Overall #2582

Revenue Y/Y Growth Statistics
High Average Low
122.2 % 18.29 % -18.91 %
IV. Quarter   (Sep 30 2018)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #373
Overall #2582
Revenue Y/Y Growth Statistics
High Average Low
122.2 % 18.29 % -18.91 %
IV. Quarter   (Sep 30 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Gilead Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
60.23 % 4.37 % -14.47 %
(March 31, 2014)  


GILD's II. Quarter Q/Q Revenue Comment
Gilead Sciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.11%, to $ 7,803.00 millions, from $6,960.00 millions in the first quarter.
GILD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Gilead Sciences Inc 's Revenue growth quarter on quarter, overall rank is 732.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #121
Overall #732
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #121
Overall #732
Revenue Q/Q Growth Statistics
High Average Low
60.23 % 4.37 % -14.47 %
(March 31, 2014)  


GILD's II. Quarter Q/Q Revenue Comment
Gilead Sciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.11%, to $ 7,803.00 millions, from $6,960.00 millions in the first quarter.
GILD is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Gilead Sciences Inc 's Revenue growth quarter on quarter, overall rank is 732.


Gilead Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 30,457.00 $ 29,736.00 $ 29,443.00 $ 29,087.00 $ 28,863.00
Y / Y Revenue Growth (TTM) 5.52 % 3.48 % 2.4 % 2.78 % 3.81 %
Year on Year Revenue Growth Overall Ranking # 2207 # 1857 # 1601 # 1690 # 1939
Seqeuential Revenue Change (TTM) 2.42 % 1 % 1.22 % 0.78 % 0.45 %
Seq. Revenue Growth (TTM) Overall Ranking # 2582 # 1461 # 2065 # 1839 # 1966


Cumulative Revenue growth Comment
Although Gilead Sciences Inc 's Annual Revenue growth year on year were below company's average 18.29% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 5.52% year on year, from 3.48% in Mar 31 2026.

In the Healthcare sector 325 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1857 to 2207.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 326
Overall # 2207

Revenue TTM Y/Y Growth Statistics
High Average Low
122.2 %
 18.29 %
-18.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 373
S&P 500 # 2582
Cumulative Revenue growth Comment
Although Gilead Sciences Inc 's Annual Revenue growth year on year were below company's average 18.29% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 5.52% year on year, from 3.48% in Mar 31 2026.

In the Healthcare sector 325 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1857 to 2207.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 326
Overall # 2207

Revenue TTM Y/Y Growth Statistics
High Average Low
122.2 %
18.29 %
-18.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 373
S&P 500 # 2582




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GILD's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Xencor Inc17.46%$ 17.458 millions
Logicmark Inc17.39%$ 17.387 millions
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions


About Gilead Sciences Inc Revenue Growth Rates (GILD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gilead Sciences Inc (CIK 882095).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000882095-26-000031
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gilead Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.